Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line
- 1 February 2022
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 22 (4), 713-720
- https://doi.org/10.2174/1871520621666210118093532
Abstract
Background: In the last decades, metformin (Met), an herbal anti-diabetic medicine, has been proposed as an anti-cancer agent. Objective: Thyroid cancers are the most common malignancy of the endocrine system. Therefore, the current study was performed to assess the effects of Met on cell proliferation and activation of the Phosphoinositide 3-Kinase (PI3K)/Protein kinase B (AKT)/Forkhead Box O1 (FOXO1) signaling pathway in the Medullary Thyroid Carcinoma (MTC) cells. The effects of Met on the expression of REarranged during Transfection (RET) proto-oncogene were also investigated. Methods: MTC cell line (TT) was treated with 0, 2.5, 5, 10, 20, 30, 40, 50, and 60 mM concentrations of Met for 24, 48, and 72h. The viability and apoptosis of the treated cells were measured by the 3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) and Annexin V- Propidium Iodide (PI) assays. The expression level of PI3K, AKT, FOXO1, and RET genes was investigated by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR), and phosphorylation of their proteins was determined by the Enzyme-Linked Immunosorbent Assay (ELISA). Results: Results showed that Met significantly decreased the viability of the MTC cells. Met also reduced the expression level of PI3K, AKT, and FOXO1 genes (P<0.05), whereas it elevated the expression level of RET proto-oncogene (P<0.05). Conclusion: It seems that the Met has cytostatic effect on the TT cells. Our results showed that anti-tumoral effects of Met may be cell type-specific, and according to the induction of RET (as a proto-oncogene) and inhibition of FOXO1 (as a tumor suppressor gene), Met could not be an appropriate agent in treatment of MTC. The antineoplastic activity of Met has been confirmed against several malignancies in "in vitro" and "in vivo" studies. However, its molecular mechanisms in the treatment of different carcinomas particularly in thyroid cancers are not clearly understood and more studies are required to confirm its exact effect on the MTC.Keywords
Funding Information
- Cellular and Molecular Endocrine Research Center, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences (852)
This publication has 36 references indexed in Scilit:
- Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascadeBMC Cancer, 2013
- Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cellsBMC Cancer, 2013
- Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent MannersPLOS ONE, 2013
- FoxO transcription factors; Regulation by AKT and 14-3-3 proteinsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Akt, FoxO and regulation of apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Suppression of FoxO1 Activity by Long-Chain Fatty Acyl AnalogsDiabetes, 2011
- Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4Biochemical and Biophysical Research Communications, 2010
- The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancerSurgery, 2008
- The role of insulin receptors and IGF-I receptors in cancer and other diseasesArchives of Physiology and Biochemistry, 2008
- Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patientsEuropean Journal of Surgical Oncology, 2007